Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Agomab Therapeutics Nv's Competitiveness

Name: Agomab Therapeutics Nv Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Agomab Therapeutics Nv (AGMB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2025

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AGMB/competitors

https://api.csimarket.com/api/v1/companies/AGMB/relationships

https://api.csimarket.com/api/v1/companies/AGMB/similar

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Business Relationships API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Agomab Therapeutics Nv's Competitor Quality Breadth

Group definitions: see Methodology: Performance Group Definitions.

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Agomab Therapeutics Nv	-	-	-	-
High-Confidence Competitors (8)
Similar-Size Competitors (10)	-

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

AGMB Stock Performance relative to its Competitors

AGMB Competitors (weighted) Percent change over the selected range

Agomab Therapeutics Nv's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(5 of 8)

Similar-Size
(0 of 8)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Agomab Therapeutics Nv	-	-
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (8)	40.4%	63.2%
Similar-Size Competitors (8)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Agomab Therapeutics Nv's competitor groups requires a Commercial License.

Unlock Full Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

AGMB Stock Performance relative to High-Confidence Competitors

AGMB High-Confidence Competitors (equal-weighted, 9) Percent change over the selected range

AGMB Stock Performance relative to Similar-Size Competitors

AGMB Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Agomab Therapeutics Nv's Comment on Competition and Industry Peers

The competitive landscape comprises technology and biopharmaceutical companies, academic research institutions, governmental agencies, and public and private institutions, some of which collaborate with large biopharmaceutical companies. Competition results from mergers and acquisitions that concentrate resources among fewer competitors, as well as competition in recruiting personnel, establishing clinical trial sites, enrolling patients, and acquiring technology. Key competitive factors include efficacy, safety, convenience, administration method, cost, promotional activity, and intellectual property protection. Competitors developing treatments for fibrotic stricturing Crohn's disease (FSCD) and Crohn's disease (CD) include RedX Pharma Ltd, Palisade Bio, and Enveda as direct competitors for FSCD product candidates. Additional competitors developing CD product candidates with potential anti-fibrotic effects include Merck & Co., Teva Pharma Ltd., Sanofi S.A., Roche Holding AG, Pfizer Inc., Spyre Therapeutics Inc., Xencor Inc., Caldera Therapeutics Inc., Boehringer Ingelheim International GmbH, Earendil Labs, and Abivax SA.

Competitor data is not yet available for Agomab Therapeutics Nv.

Agomab Therapeutics Nv's Competitors Named by the Company

Competitive relationships identified from Agomab Therapeutics Nv reports and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Abivax SA	Company report	85%	2022 to 2026	3
Merck & Co.	Company report	85%	2022 to 2026	3
Sanofi S.A.	Company report	85%	2022 to 2026	3
Earendil Labs	Company report	85%	2022 to 2026	3
RedX Pharma Ltd	Company report	85%	2022 to 2026	3
Xencor Inc	Company report	85%	2022 to 2026	3
Boehringer Ingelheim International GmbH	Company report	85%	2022 to 2026	3
Palisade Bio	Company report	85%	2022 to 2026	3
Spyre Therapeutics Inc.	Company report	85%	2022 to 2026	3
Enveda	Company report	85%	2022 to 2026	3
Roche Holding AG	Company report	85%	2022 to 2026	3
Caldera Therapeutics Inc.	Company report	85%	2022 to 2026	3
Pfizer Inc.	Company report	85%	2022 to 2026	3
Teva Pharma Ltd.	Company report	85%	2022 to 2026	3

Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Agomab Therapeutics Nv's named competitors require a Commercial License.

Unlock Full Access

Methodology: see Methodology: Peer & Competitor Identification, Sourcing.